49.87
前日終値:
$51.05
開ける:
$50.97
24時間の取引高:
771.74K
Relative Volume:
0.75
時価総額:
$3.49B
収益:
$45.48M
当期純損益:
$169.95M
株価収益率:
19.03
EPS:
2.62
ネットキャッシュフロー:
$230.85M
1週間 パフォーマンス:
-9.77%
1か月 パフォーマンス:
-8.29%
6か月 パフォーマンス:
+29.70%
1年 パフォーマンス:
+47.89%
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
名前
Protagonist Therapeutics Inc
セクター
電話
(510) 474-0170
住所
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
PTGX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
PTGX
Protagonist Therapeutics Inc
|
49.87 | 3.49B | 45.48M | 169.95M | 230.85M | 2.62 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.41 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
538.11 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
546.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
240.99 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
2024-12-06 | 開始されました | Goldman | Neutral |
2024-11-05 | 開始されました | Wedbush | Outperform |
2024-09-24 | 開始されました | TD Cowen | Buy |
2024-09-09 | 開始されました | Truist | Buy |
2023-10-30 | 開始されました | CapitalOne | Overweight |
2023-05-25 | 再開されました | Jefferies | Buy |
2022-08-25 | 開始されました | JMP Securities | Mkt Outperform |
2022-02-11 | 開始されました | BTIG Research | Buy |
2021-10-12 | アップグレード | JP Morgan | Neutral → Overweight |
2021-10-11 | アップグレード | Northland Capital | Market Perform → Outperform |
2021-09-20 | ダウングレード | JP Morgan | Overweight → Neutral |
2021-05-24 | 開始されました | JMP Securities | Mkt Outperform |
2021-05-24 | 開始されました | Northland Capital | Outperform |
2021-01-06 | 開始されました | JP Morgan | Overweight |
2020-12-16 | 開始されました | Piper Sandler | Overweight |
2020-09-18 | 繰り返されました | H.C. Wainwright | Buy |
2020-07-15 | 開始されました | Jefferies | Buy |
2020-05-18 | 繰り返されました | H.C. Wainwright | Buy |
2019-07-08 | 開始されました | H.C. Wainwright | Buy |
2019-05-09 | アップグレード | Stifel | Hold → Buy |
2018-12-06 | 開始されました | Nomura | Buy |
2018-01-29 | 開始されました | Stifel | Buy |
2017-07-21 | 開始されました | BTIG Research | Buy |
すべてを表示
Protagonist Therapeutics Inc (PTGX) 最新ニュース
10 Biotech Stocks Screaming a Buy - Insider Monkey
Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth By Investing.com - Investing.com South Africa
Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth - Investing.com
BIOTECHNOLOGY VALUE FUND L P's Strategic Acquisition in Protagonist Therapeutics Inc - GuruFocus
Citigroup Initiates Coverage on Protagonist Therapeutics (PTGX) with a 'Buy' Rating | PTGX Stock News - GuruFocus
Protagonist Therapeutics (PTGX) Initiated at Buy by Citi with $7 - GuruFocus
Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target - MarketScreener
Protagonist Therapeutics (PTGX) Initiated at Buy by Citi with $72 Target | PTGX Stock News - GuruFocus
How To Trade (PTGX) - news.stocktradersdaily.com
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
GAMMA Investing LLC Raises Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insider Sells $570,300.00 in Stock - MarketBeat
Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com Canada
Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Subdued Growth No Barrier To Protagonist Therapeutics, Inc. (NASDAQ:PTGX) With Shares Advancing 27% - simplywall.st
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 - The Columbus Dispatch
Protagonist Therapeutics (NASDAQ:PTGX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Hennion & Walsh Asset Management Inc. Has $1.26 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
California State Teachers Retirement System Sells 316 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Upgraded to “Hold” at Wall Street Zen - Defense World
Protagonist Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:PTGX - Benzinga
Exploring Three High Growth Tech Stocks In The US Market - Yahoo Finance
(PTGX) Long Term Investment Analysis - news.stocktradersdaily.com
Protagonist Therapeutics (NASDAQ:PTGX) Cut to "Sell" at Wall Street Zen - MarketBeat
Protagonist Therapeutics’ (PTGX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Protagonist-Takeda, Novartis post phase III wins - BioWorld MedTech
H.C. Wainwright reaffirms Buy rating on Protagonist Therapeutics stock By Investing.com - Investing.com UK
BTIG maintains buy rating on Protagonist Therapeutics stock By Investing.com - Investing.com UK
Protagonist Therapeutics (PTGX) Rating and Price Target Reaffirmed | PTGX Stock News - GuruFocus
Protagonist Therapeutics: Promising Future with Rusfertide as a Standard of Care for Polycythemia Vera - TipRanks
ASCO 2025: Protagonist-Takeda, Novartis post phase III wins - BioWorld MedTech
Transcript : Protagonist Therapeutics, Inc.Special Call - marketscreener.com
Protagonist Therapeutics, Inc. and Takeda Announce Asco Plenary Presentation Highlighting Full 32-Week Results from Phase 3 Verify Study of Rusfertide - marketscreener.com
Protagonist Therapeutics, Takeda's Potential Polycythemia Vera Drug Meets Primary Endpoint - marketscreener.com
Protagonist Therapeutics (PTGX): Promising Phase 3 Results for R - GuruFocus
Protagonist Therapeutics (PTGX): Promising Phase 3 Results for Rusfertide | PTGX Stock News - GuruFocus
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera - Quantisnow
Protagonist Therapeutics (NASDAQ:PTGX) Downgraded to Sell Rating by Wall Street Zen - Defense World
Cache Advisors LLC Makes New $392,000 Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome - MSN
D. E. Shaw & Co. Inc. Sells 21,121 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Bank of America Corp DE Has $5.21 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics’ SWOT analysis: stock poised for growth amid clinical advancements - Investing.com India
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Position Reduced by Ameriprise Financial Inc. - Defense World
Protagonist Therapeutics' (PTGX) Buy Rating Reiterated at HC Wainwright - MarketBeat
BNP Paribas Financial Markets Has $751,000 Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics earnings missed by $0.13, revenue fell short of estimates - Investing.com Canada
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 | PTGX Stock News - GuruFocus
Exclusive: Protagonist Therapeutics CEO Reveals Company Strategy at Major Jefferies Healthcare Conference - Stock Titan
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of “Buy” from Analysts - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Given “Buy” Rating at HC Wainwright - Defense World
Protagonist Therapeutics Inc (PTGX) 財務データ
収益
当期純利益
現金流量
EPS
Protagonist Therapeutics Inc (PTGX) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
MOLINA ARTURO MD | Chief Medical Officer |
Jun 10 '25 |
Option Exercise |
8.04 |
10,000 |
80,400 |
93,892 |
MOLINA ARTURO MD | Chief Medical Officer |
Jun 10 '25 |
Sale |
57.03 |
10,000 |
570,300 |
83,892 |
MOLINA ARTURO MD | Chief Medical Officer |
Jun 09 '25 |
Sale |
55.51 |
10,000 |
555,100 |
83,892 |
大文字化:
|
ボリューム (24 時間):